About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Publications
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies
Publications
Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis
Publications
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Publications
Sex-related Differences in Patient Characteristics, and Efficacy and Safety of Advanced Therapies in Randomised Clinical Trials in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Publications
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two Phase 3 randomized trials in plaque psoriasis
Publications
Long-term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Publications
Effects of 1-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis
Publications
Global, Regional, and National Burden of Other Musculoskeletal Disorders, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021
Publications
Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis
Publications
Risk of Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic, Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drugs: Observational Data from the German RABBIT Register
Publications
Therapy with JAK Inhibitors or bDMARDs and the Risk of Cardiovascular Events in the Dutch Rheumatoid Arthritis Population
Publications
Bimekizumab Treatment in Patients With Active Axial Spondyloarthritis: 52-week Efficacy and Safety from the Randomised Parallel Phase 3 BE MOBILE 1 and BE MOBILE 2 Studies
Publications
Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data
Publications
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Publications
Global, Regional, and National Burden of Rheumatoid Arthritis, 1990–2020, and Projections to 2050: a Systematic Analysis of the Global Burden of Disease Study 2021
Publications
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis
Publications
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Publications
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study
Publications
Anti-GM-CSF Otilimab Versus Tofacitinib or Placebo in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Conventional or Biologic DMARDs: Two Phase 3 Randomised Trials (contRAst 1 and contRAst 2)
Publications
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
Publications
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from the Phase III, Randomised, Placebo-Controlled, Active Reference BE OPTIMAL Study
Publications
Anti-gm-csf Otilimab versus Sarilumab or Placebo in Patients with Rheumatoid Arthritis and Inadequate Response to Targeted Therapies: A Phase III Randomised Trial (contRAst 3)
Publications
Janus Kinase Inhibitor—Tofacitinib Associated with Pemphigus: An Analysis of the FDA Adverse Event Reporting System Data
Publications
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials
Publications
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
Publications
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients with Active Ankylosing Spondylitis
Publications
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
Publications
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT Phase 3b trial
Publications
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Publications
Differential Properties of Janus Kinase Inhibitors in the Treatment of Immune-mediated Inflammatory Diseases
Publications
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Publications